CA3052195A1 - Small molecule antagonists of sumo related modification of crmp2 and uses thereof - Google Patents
Small molecule antagonists of sumo related modification of crmp2 and uses thereof Download PDFInfo
- Publication number
- CA3052195A1 CA3052195A1 CA3052195A CA3052195A CA3052195A1 CA 3052195 A1 CA3052195 A1 CA 3052195A1 CA 3052195 A CA3052195 A CA 3052195A CA 3052195 A CA3052195 A CA 3052195A CA 3052195 A1 CA3052195 A1 CA 3052195A1
- Authority
- CA
- Canada
- Prior art keywords
- benzo
- piperidin
- imidazol
- methanone
- fluorobenzyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/08—Radicals containing only hydrogen and carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454475P | 2017-02-03 | 2017-02-03 | |
| US62/454,475 | 2017-02-03 | ||
| US201762506298P | 2017-05-15 | 2017-05-15 | |
| US62/506,298 | 2017-05-15 | ||
| PCT/US2018/016687 WO2018144900A1 (en) | 2017-02-03 | 2018-02-02 | Small molecule antagonists of sumo related modification of crmp2 and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3052195A1 true CA3052195A1 (en) | 2018-08-09 |
Family
ID=63041159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3052195A Pending CA3052195A1 (en) | 2017-02-03 | 2018-02-02 | Small molecule antagonists of sumo related modification of crmp2 and uses thereof |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11208397B2 (https=) |
| EP (1) | EP3576734A4 (https=) |
| JP (1) | JP7092776B2 (https=) |
| CN (1) | CN110381941A (https=) |
| AU (1) | AU2018215466B2 (https=) |
| CA (1) | CA3052195A1 (https=) |
| WO (1) | WO2018144900A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2025129167A1 (en) * | 2023-12-15 | 2025-06-19 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Services | Inhibitors of the surface expression of the voltage-gated sodium ion channel 1.7 (nav1.7) and their therapeutic uses |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3989816A (en) | 1975-06-19 | 1976-11-02 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacycloheptan-2-ones |
| US4444762A (en) | 1980-04-04 | 1984-04-24 | Nelson Research & Development Company | Vehicle composition containing 1-substituted azacyclopentan-2-ones |
| US7205404B1 (en) | 1999-03-05 | 2007-04-17 | Metabasis Therapeutics, Inc. | Phosphorus-containing prodrugs |
| JP2003512372A (ja) * | 1999-10-18 | 2003-04-02 | スミスクライン ビーチャム パブリック リミテッド カンパニー | テトラヒドロベンゾインドロン誘導体、それらの製造および５−ｈｔ７受容体アンタゴニストとしてのそれらの使用 |
| EP2240464A4 (en) * | 2008-02-12 | 2011-09-14 | Yuhan Corp | PROCESS FOR THE PREPARATION OF 2-METHYL-2'-PHENYLPROPIONIC ACID DERIVATIVES AND NOVEL INTERMEDIATE PRODUCTS |
| EP2681200A4 (en) | 2011-03-03 | 2015-05-27 | Zalicus Pharmaceuticals Ltd | INHIBITORS OF BENZIMIDAZOLE TYPE OF SODIUM CHANNEL |
| CN102627631B (zh) * | 2012-03-31 | 2013-07-24 | 中国药科大学 | 苯并杂环类化合物、其制备方法及其医药用途 |
| US9828348B2 (en) * | 2013-11-08 | 2017-11-28 | Purdue Pharma L.P. | Benzimidazole derivatives and use thereof |
| EP3119415A4 (en) | 2014-03-07 | 2017-11-29 | The Arizona Board of Regents on behalf of the University of Arizona | Non-narcotic crmp2 peptides targeting sodium channels for chronic pain |
| JP2018052817A (ja) * | 2015-01-21 | 2018-04-05 | 大日本住友製薬株式会社 | 新規ベンズイミダゾール誘導体およびその医薬用途 |
| EP3359151A4 (en) * | 2015-10-07 | 2019-08-14 | Arizona Board of Regents on behalf of the University of Arizona | CRMP2 SUMOYLATION INHIBITORS AND USES THEREOF |
-
2018
- 2018-02-02 AU AU2018215466A patent/AU2018215466B2/en active Active
- 2018-02-02 CN CN201880015053.7A patent/CN110381941A/zh active Pending
- 2018-02-02 JP JP2019542201A patent/JP7092776B2/ja active Active
- 2018-02-02 CA CA3052195A patent/CA3052195A1/en active Pending
- 2018-02-02 WO PCT/US2018/016687 patent/WO2018144900A1/en not_active Ceased
- 2018-02-02 EP EP18748594.1A patent/EP3576734A4/en not_active Withdrawn
- 2018-02-02 US US16/483,644 patent/US11208397B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| EP3576734A4 (en) | 2020-12-09 |
| EP3576734A1 (en) | 2019-12-11 |
| CN110381941A (zh) | 2019-10-25 |
| AU2018215466A1 (en) | 2019-08-22 |
| WO2018144900A1 (en) | 2018-08-09 |
| JP7092776B2 (ja) | 2022-06-28 |
| US20200277271A1 (en) | 2020-09-03 |
| JP2020505434A (ja) | 2020-02-20 |
| AU2018215466B2 (en) | 2022-03-10 |
| US11208397B2 (en) | 2021-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101553256B (zh) | 苯基丙酰胺化合物及其用途 | |
| JP2003516391A (ja) | ムスカリン性レセプターアンタゴニスト活性を有するウレア化合物 | |
| RS56332B1 (sr) | Antagonisti c5ar | |
| RS54998B1 (sr) | Antagonisti c5ar | |
| TW200940526A (en) | Pyridyl non-aromatic nitrogenated heterocyclic-1-carboxylate ester derivative | |
| JPH09505036A (ja) | 喘息治療用のニューロキニン２受容体拮抗薬としての新規な４−ピペリジニル置換ラクタム | |
| US12162861B2 (en) | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
| TW200812963A (en) | Benzenesulfonamide compounds and the use thereof | |
| TW200815353A (en) | Benzenesulfonamide compounds and their use | |
| BR112019001926A2 (pt) | moduladores do receptor nmda espiro-lactama e bis-espiro-lactama e usos destes | |
| EP2119704A1 (en) | Acylguanidine derivative | |
| JP2009507800A (ja) | 縮合およびスピロ環化合物ならびにその使用 | |
| AU2024219951A1 (en) | Dopamine D3 receptor selective antagonists/partial agonists and uses thereof | |
| JP7783174B2 (ja) | 四員環誘導体の調節剤、調製方法及びその利用 | |
| Layton et al. | Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists | |
| JP7434265B2 (ja) | アンドロゲン受容体結合分子およびその使用 | |
| AU2018215466B2 (en) | Small molecule antagonists of SUMO related modification of CRMP2 and uses thereof | |
| BR112015009243B1 (pt) | Composto de amina cíclico fluorosubstituído, método para preparar um composto de amina cíclico fluorosubstituído, composição farmacêutica, inibidor de acetilcolinesterase e uso do composto de amina cíclico fluorosubstituído | |
| TW202448467A (zh) | 靶記細胞狀態之技術 | |
| EP3768679B1 (en) | Biased potent opioid-like agonists as improved medications to treat chronic and acute pain and methods of using the same | |
| US11299476B2 (en) | Dopamine D3 receptor selective antagonists/partial agonists; method of making; and use thereof | |
| RU2813232C2 (ru) | Соединение изоиндолин, способ получения, фармацевтическая композиция и их применение | |
| AU2023353560A1 (en) | Dopamine d3/d2 receptor partial agonists for the treatment of neuropsychiatric disorders | |
| EP1666464A1 (en) | Piperidine derivative having nmda receptor antagonistic activity | |
| JP2025507902A (ja) | ヒスタミンｈ３受容体阻害剤及びその医薬における使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220907 |